Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 8:33 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 337–360 of 868 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Lung Cancer Recurrent Clear all
Terminated Phase 1 Interventional

IR-guided Ablation (IRGA) Combined With Stereotactic Ablative Radiation (SABR) for Large Lung Tumors

NCT01746810
View directory record Official record
Conditions
Recurrent Non-small Cell Lung Cancer
Interventions
Stereotactic body RT and IRGA
Radiation
Lead sponsor
New Mexico Cancer Research Alliance
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Nov 17, 2017 · Synced Oct 23, 2026, 8:33 AM EDT
Not listed Phase 2 Interventional

Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.

NCT03544723
View directory record Official record
Conditions
Solid Tumor, Lymphoma
Interventions
Ad-p53
Drug
Lead sponsor
MultiVir, Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
3
States / cities
Chicago, Illinois • Morristown, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 9, 2020 · Synced Oct 23, 2026, 8:33 AM EDT
Completed Not applicable Interventional

Quality of Life and Survivorship Care in Patients Undergoing Hyperthermic Intraperitoneal Chemotherapy (HIPEC)

NCT01126346
View directory record Official record
Conditions
Advanced Malignant Mesothelioma, Carcinoma of the Appendix, Ovarian Sarcoma, Ovarian Stromal Cancer, Pseudomyxoma Peritonei, Recurrent Colon Cancer, Recurrent Malignant Mesothelioma, Recurrent Ovarian Epithelial Cancer, Recurrent Ovarian Germ Cell Tumor, Stage III Colon Cancer, Stage III Ovarian Epithelial Cancer, Stage III Ovarian Germ Cell Tumor, Stage IV Colon Cancer, Stage IV Ovarian Epithelial Cancer, Stage IV Ovarian Germ Cell Tumor, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
HIPEC Orientation, Consultation with Survivorship Navigator, Questionnaires
Behavioral · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
Not listed
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 3, 2018 · Synced Oct 23, 2026, 8:33 AM EDT
Completed Phase 1 Interventional

Gene Therapy in Treating Patients With Cancer

NCT00004178
View directory record Official record
Conditions
Cancer
Interventions
therapeutic autologous lymphocytes
Biological
Lead sponsor
Roger Williams Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2001
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 10, 2011 · Synced Oct 23, 2026, 8:33 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Lepirudin in Treating Patients With Recurrent or Advanced Small Cell Lung Cancer

NCT00003726
View directory record Official record
Conditions
Lung Cancer
Interventions
lepirudin
Biological
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years to 120 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2001
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Aug 8, 2016 · Synced Oct 23, 2026, 8:33 AM EDT
Withdrawn Phase 1Phase 2 Interventional

Sorafenib and High-Dose Carboplatin, Paclitaxel, and External-Beam Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer

NCT00547443
View directory record Official record
Conditions
Lung Cancer
Interventions
carboplatin, paclitaxel, sorafenib tosylate, radiation therapy
Drug · Radiation
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
2
States / cities
Arlington, Texas • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 10, 2019 · Synced Oct 23, 2026, 8:33 AM EDT
Terminated Phase 1 Interventional

A Vaccine Trial for Patients With Stage IIIB, IV, or Recurrent Non-Small Cell Lung Cancer

NCT01574222
View directory record Official record
Conditions
Non-Small Cell Lung Cancer (NSCLC)
Interventions
autologous dendritic cell adenovirus CCL21 vaccine
Biological
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
21 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
West Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 18, 2018 · Synced Oct 23, 2026, 8:33 AM EDT
Completed Phase 3 Interventional

Carboplatin and Paclitaxel With or Without ISIS 3521 in Treating Patients With Non-Small Cell Lung Cancer

NCT00017407
View directory record Official record
Conditions
Lung Cancer
Interventions
ISIS 3521, carboplatin, paclitaxel
Biological · Drug
Lead sponsor
Ionis Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2002
U.S. locations
2
States / cities
Carlsbad, California • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 5, 2022 · Synced Oct 23, 2026, 8:33 AM EDT
Completed Phase 1 Interventional

Safety Study of Nivolumab With Nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, Nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or Nab-Paclitaxel in Recurrent Metastatic Breast Cancer

NCT02309177
View directory record Official record
Conditions
Breast Neoplasms, Pancreatic Neoplasms
Interventions
nab-Paclitaxel, Nivolumab, Gemcitabine, Carboplatin
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
15
States / cities
Sacramento, California • Santa Monica, California • New Haven, Connecticut + 11 more
Source: ClinicalTrials.gov public record
Updated May 31, 2019 · Synced Oct 23, 2026, 8:33 AM EDT
Completed Phase 2 Interventional

Fenretinide in Treating Patients With Recurrent Small Cell Lung Cancer

NCT00009971
View directory record Official record
Conditions
Lung Cancer
Interventions
fenretinide
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
2
States / cities
Ann Arbor, Michigan • Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 11, 2013 · Synced Oct 23, 2026, 8:33 AM EDT
Terminated Phase 1 Interventional

Study of CM-24 (MK-6018) Alone and In Combination With Pembrolizumab (MK-3475) in Participants With Selected Advanced or Recurrent Malignancies (MK-6018-001)

NCT02346955
View directory record Official record
Conditions
Non-small Cell Lung Carcinoma (NSCLC), Melanoma, Bladder Cancer, Colorectal Cancer, Gastric Cancer, Ovarian Cancer
Interventions
CM-24 (MK-6018), Pembrolizumab (MK-3475)
Biological
Lead sponsor
Famewave Ltd.
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
2
States / cities
Los Angeles, California • New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 27, 2020 · Synced Oct 23, 2026, 8:33 AM EDT
Completed No phase listed Observational

Study of Symptoms Caused by Cancer and Cancer Therapy in Patients With Invasive Breast, Lung, Prostate, or Colorectal Cancer

NCT00303914
View directory record Official record
Conditions
Breast Cancer, Cognitive/Functional Effects, Colorectal Cancer, Lung Cancer, Pain, Prostate Cancer, Psychosocial Effects of Cancer and Its Treatment
Interventions
assessment of therapy complications, cognitive assessment, psychosocial assessment and care
Procedure
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years to 120 Years
Enrollment
2,310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
32
States / cities
Chicago, Illinois • Evanston, Illinois • Elkhart, Indiana + 19 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2023 · Synced Oct 23, 2026, 8:33 AM EDT
Completed Phase 2 Interventional

A Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Squamous Cell Carcinoma of the Lung

NCT00998192
View directory record Official record
Conditions
Metastatic or Recurrent Squamous Cell Carcinoma of the Lung
Interventions
REOLYSIN, Paclitaxel, Carboplatin
Biological · Drug
Lead sponsor
Oncolytics Biotech
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
17
States / cities
Los Angeles, California • Ocala, Florida • Niles, Illinois + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2016 · Synced Oct 23, 2026, 8:33 AM EDT
Active, not recruiting Phase 1 Interventional

A First-in-human Study to Learn How Safe the Study Drug BAY3375968, an Anti-CCR8 Antibody, is, When Given Alone or in Combination With Pembrolizumab, How it Affects the Body, How it Moves Into, Through, and Out of the Body, and to Find the Best Dose in Participants With Advanced Solid Tumors

NCT05537740
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
BAY3375968, Pembrolizumab
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
4
States / cities
Chicago, Illinois • Chapel Hill, North Carolina • San Antonio, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 23, 2026, 8:33 AM EDT
Terminated Phase 1 Interventional

Everolimus, Carboplatin, and Etoposide in Treating Patients With Small Cell Lung Cancer or Other Advanced Solid Tumors

NCT00807755
View directory record Official record
Conditions
Lung Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
Carboplatin, Etoposide, RAD001
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jan 9, 2018 · Synced Oct 23, 2026, 8:33 AM EDT
Completed Phase 2 Interventional

Vaccine Therapy Plus Biological Therapy in Treating Adults With Metastatic Solid Tumors

NCT00019331
View directory record Official record
Conditions
Colorectal Cancer, Endometrial Cancer, Head and Neck Cancer, Liver Cancer, Lung Cancer, Melanoma (Skin), Pancreatic Cancer, Testicular Germ Cell Tumor, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
aldesleukin, ras peptide cancer vaccine, sargramostim, DetoxPC
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 20, 2013 · Synced Oct 23, 2026, 8:33 AM EDT
Completed Phase 1 Interventional

INC280 and Erlotinib Hydrochloride in Treating Patients With Non-small Cell Lung Cancer

NCT01911507
View directory record Official record
Conditions
Recurrent Non-small Cell Lung Cancer
Interventions
INC280, erlotinib hydrochloride
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
2
States / cities
Sacramento, California • San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 13, 2021 · Synced Oct 23, 2026, 8:33 AM EDT
Completed Phase 2 Interventional Results available

Pemetrexed Disodium With or Without Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV or Recurrent Non-Small Cell Lung Cancer

NCT00950365
View directory record Official record
Conditions
Bronchioloalveolar Carcinoma, Large Cell Lung Carcinoma, Lung Adenocarcinoma, Recurrent Non-Small Cell Lung Carcinoma, Stage IIIB Non-Small Cell Lung Cancer, Stage IV Non-Small Cell Lung Cancer
Interventions
Erlotinib Hydrochloride, Laboratory Biomarker Analysis, Pemetrexed Disodium
Drug · Other
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2017
U.S. locations
5
States / cities
Sacramento, California • Worcester, Massachusetts • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Sep 16, 2020 · Synced Oct 23, 2026, 8:33 AM EDT
Terminated Phase 1Phase 2 Interventional

Gemcitabine Plus Paclitaxel in Treating Patients With Advanced Non-small Cell Lung Cancer or Other Solid Tumor

NCT00004159
View directory record Official record
Conditions
Lung Cancer
Interventions
gemcitabine hydrochloride, paclitaxel
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Nov 20, 2013 · Synced Oct 23, 2026, 8:33 AM EDT
Terminated Not applicable Interventional

Yoga in Improving Quality of Life in Patients With Non-small Cell Lung Cancer Undergoing Treatment

NCT02895503
View directory record Official record
Conditions
Non-small Cell Lung Cancer, Recurrent Non-Small Cell Lung Carcinoma
Interventions
Yoga, Support Group Therapy, FACT-L, Pulmonary function test
Behavioral · Other
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
Not listed
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 9, 2016 · Synced Oct 23, 2026, 8:33 AM EDT
Recruiting Phase 2 Interventional

Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer

NCT04614103
View directory record Official record
Conditions
Metastatic Non Small Cell Lung Cancer
Interventions
LN-145
Biological
Lead sponsor
Iovance Biotherapeutics, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2031
U.S. locations
27
States / cities
Gilbert, Arizona • Miami, Florida • Tampa, Florida + 21 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Oct 23, 2026, 8:33 AM EDT
Terminated Phase 2 Interventional Results available

Docetaxel and Cisplatin in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

NCT00118131
View directory record Official record
Conditions
Lung Cancer
Interventions
cisplatin, docetaxel
Drug
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
18 Years to 120 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
13
States / cities
East Brunswick, New Jersey • Edison, New Jersey • Freehold, New Jersey + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2023 · Synced Oct 23, 2026, 8:33 AM EDT
Completed Phase 2 Interventional

A Study to Evaluate the Single-Agent Lenalidomide in Subjects With Recurrent Non-Small-Cell Lung Cancer

NCT00179686
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
CC-5013
Drug
Lead sponsor
Celgene Corporation
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
6
States / cities
Birmingham, Alabama • Chicago, Illinois • Metairie, Louisiana + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2006 · Synced Oct 23, 2026, 8:33 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Navitoclax and Vistusertib in Treating Patients With Relapsed Small Cell Lung Cancer and Other Solid Tumors

NCT03366103
View directory record Official record
Conditions
Metastatic Malignant Solid Neoplasm, Recurrent Lung Small Cell Carcinoma, Recurrent Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm, Stage III Lung Small Cell Carcinoma, by American Joint Committee on Cancer (AJCC) v7, Stage IIIA Lung Small Cell Carcinoma AJCC v7, Stage IIIB Lung Small Cell Carcinoma AJCC v7, Stage IV Lung Small Cell Carcinoma AJCC v7, Unresectable Solid Neoplasm
Interventions
Navitoclax, Vistusertib
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
14
States / cities
Los Angeles, California • Baltimore, Maryland • Boston, Massachusetts + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 17, 2023 · Synced Oct 23, 2026, 8:33 AM EDT